This protocol is designed to efficiently quantify ubiquitin-proteasome system (UPS) activity in different cellular compartments of the rodent brain. Users are able to examine UPS functioning in nuclear, cytoplasmic and synaptic fractions in the same animal, reducing the amount of time and number of animals needed to perform these complex analyses.
The ubiquitin-proteasome system is a key regulator of protein degradation and a variety of other cellular processes in eukaryotes. In the brain, increases in ubiquitin-proteasome activity are critical for synaptic plasticity and memory formation and aberrant changes in this system are associated with a variety of neurological, neurodegenerative and psychiatric disorders. One of the issues in studying ubiquitin-proteasome functioning in the brain is that it is present in all cellular compartments, in which the protein targets, functional role and mechanisms of regulation can vary widely. As a result, the ability to directly compare brain ubiquitin protein targeting and proteasome catalytic activity in different subcellular compartments within the same animal is critical for fully understanding how the UPS contributes to synaptic plasticity, memory and disease. The method described here allows collection of nuclear, cytoplasmic and crude synaptic fractions from the same rodent (rat) brain, followed by simultaneous quantification of proteasome catalytic activity (indirectly, providing activity of the proteasome core only) and linkage-specific ubiquitin protein tagging. Thus, the method can be used to directly compare subcellular changes in ubiquitin-proteasome activity in different brain regions in the same animal during synaptic plasticity, memory formation and different disease states. This method can also be used to assess the subcellular distribution and function of other proteins within the same animal.
The ubiquitin-proteasome system (UPS) is a complex network of interconnected protein structures and ligases that controls the degradation of most short-lived proteins in cells1. In this system, proteins are marked for degradation or other cellular processes/fates by the small modifier ubiquitin. A target protein can acquire 1-7 ubiquitin modifications, which can link together at one of seven lysine (K) sites (K6, K11, K27, K29, K33, K48 and K63) or the N-terminal methionine (M1; as known as linear) in the previous ubiquitin2. Some of these polyubiquitin tags are degradation-specific (K48)3, while others are largely independent of the protein degradation process (M1)4,5,6. Thus, the protein ubiquitination process is incredibly complex and the ability to quantify changes in a specific polyubiquitin tag is critical for ultimately understanding the role of that given modification in cellular functioning. Further complicating the study of this system, the proteasome, which is the catalytic structure of the UPS7, both degrades proteins but can also be involved in other non-proteolytic processes8,9. Not surprisingly then, since its initial discovery, normal and aberrant ubiquitin-proteasome activity has been implicated in long-term memory formation and a variety of disease states, including many neurological, neurodegenerative and psychiatric disorders10,11. As a result, methods which can effectively and efficiently quantify UPS activity in the brain are critical for ultimately understanding how this system is dysregulated in disease states and the eventual development of treatment options targeting ubiquitin and/or proteasome functioning.
There are a number of issues in quantifying ubiquitin-proteasome activity in brain tissue from rats and mice, which are the most common model systems used to study UPS function, including 1) the diversity of ubiquitin modifications, and 2) distribution and differential regulation of UPS functioning across subcellular compartments12,13,14. For example, many of the early demonstrations of ubiquitin-proteasome function in the brain during memory formation used whole cell lysates and indicated time-dependent increases in both protein ubiquitination and proteasome activity15,16,17,18,19,20. However, we recently found that ubiquitin-proteasome activity varied widely across subcellular compartments in response to learning, with simultaneous increases in some regions and decreases in others, a pattern that differs significantly from what was previously reported in whole cell lysates21. This is consistent with the limitation of a whole cell approach, as it cannot dissociate the contribution of changes in UPS activity across different subcellular compartments. Though more recent studies have employed synaptic fraction protocols to study the UPS specifically at synapses in response to learning22,23,24, the methods used occlude the ability to measure nuclear and cytoplasmic ubiquitin-proteasome changes in the same animal. This results in an unnecessary need to repeat experiments multiple times, collecting a different subcellular fraction in each. Not only does this result in a greater loss of animal lives, but it eliminates the ability to directly compare UPS activity across different subcellular compartments in response to a given event or during a specific disease state. Considering that protein targets of ubiquitin and the proteasome vary widely throughout the cell, understanding how ubiquitin-proteasome signaling differs in distinct subcellular compartments is critical for identifying the functional role of the UPS in the brain during memory formation and neurological, neurodegenerative and psychiatric disorders.
To address this need, we recently developed a procedure in which nuclear, cytoplasmic and synaptic fractions could be collected for a given brain region from the same animal21. Additionally, to account for the limited amount of protein that can be obtained from collecting multiple subcellular fractions from the same sample, we optimized previously established protocols to assay in vitro proteasome activity and linkage-specific protein ubiquitination in lysed cells collected from rodent brain tissue. Using this protocol, we were able to collect and directly compare learning-dependent changes in proteasome activity, K48, K63, M1 and overall protein polyubiquitination levels in the nucleus and cytoplasm and at synapses in the lateral amygdala of rats. Here, we describe in detail our procedure (Figure 1), which could significantly improve our understanding of how the UPS is involved in long-term memory formation and various disease states. However, it should be noted that the in vitro proteasome activity discussed in our protocol, while widely used, does not directly measure the activity of complete 26S proteasome complexes. Rather, this assay measures the activity of the 20S core, meaning it can only serve as a proxy to understand the activity of the core itself as opposed to the entire 26S proteasome complex.
All procedures including animal subjects have been approved by the Virginia Polytechnic Institute and State University Institutional Animal Care and Use Committee (IACUC).
1. Collection and Dissection of Rodent Brain Tissue
NOTE: This protocol can be applied to a variety of brain regions and used with various tissue collection procedures. Below is the procedure used in our lab for subcellular of rat brain tissue, using 8-9 week old male Sprague Dawley rats. In order to process all cellular compartments in the same animal, section 1.3. must be followed regardless of the tissue collection procedure used.
2. Nuclear and Cytoplasmic Extraction
NOTE: This protocol uses premade stock solutions of common lab chemicals, including 0.1 M HEPES, 1 M MgCl2, 1 M Dithiothreitol (DTT), 0.5 M ethylenediaminetetraacetic acid (EDTA), 5 M NaCl, 10% NP-40 (IGEPAL) and 50% glycerol. If endpoint is used in proteasome activity assays, glycerol and ATP can be added to all buffers to help prevent disassembly of proteasome complexes during lysis.
3. Synaptic Fraction Collection
NOTE: This protocol uses premade stock solutions of common lab chemicals, including 1 M Tris (pH 7.5), 0.5 M EDTA, 5 M NaCl and 10% SDS. If endpoint is used in proteasome activity assays, glycerol and ATP can be added to all buffers to help prevent disassembly of proteasome complexes during lysis
4. Proteasome Activity Assay
NOTE: Proteasome activity can be measured in homogenized brain tissue using a slightly modified version of the 20S Proteasome Activity Kit. This assay does not directly measure the activity of complete 26S proteasome complexes. Rather, it measures the activity of the 20S core, meaning it can only serve as a proxy to understand the activity of the core itself as opposed to the entire 26S proteasome complex. The success of this assay declines with repeated freeze-thaw cycles and/or increasing levels of detergents, particularly ionic, and requires the use of a plate reader with a 360/460 (excitation/emission) filter set and heating capabilities up to 37 °C.
5. Quantification of Linkage-specific Protein Ubiquitination
Using the procedure described here, nuclear, cytoplasmic and synaptic fractions were collected from the lateral amygdala of the rat brain (Figure 1). Purity of the individual fractions were confirmed via Western blotting, probing with antibodies against proteins that should be enriched or depleted in the lysate. In the first hemisphere where a crude synaptic fraction was collected, postsynaptic density protein 95 (PSD95) was present in the synaptic, but not nuclear, fraction, with lower levels in the cytoplasm (Figure 2A). This is consistent with previous work demonstrating that the synaptic fraction preparation isolates both presynaptic and postsynaptic components25. Conversely, the nuclear protein histone H3 was present in the nuclear, but not the synaptic, fraction, with lower levels in the cytoplasm (Figure 2B). The presence of PSD95 and H3 in the cytoplasm is consistent with their cytoplasmic translation. The cytoplasmic protein β-tubulin was present in our cytoplasmic fraction, but was largely absent from the nuclear lysate (Figure 2C), with lower levels in the synaptic region. This suggests that we were able to produce a nuclear fraction that was largely absent of cytoplasmic proteins. The presence of tubulin in the synaptic region is consistent with previous studies26. All three fractions showed similar levels of the housing keeping protein β-actin (Figure 2D), which was used as a loading control. Collectively, these results confirm that the purity of the nuclear, cytoplasmic and synaptic fractions collected from a single rat lateral amygdala.
Next, all lysates were confirmed for functional proteasome activity using the described modified version of the in vitro 20S proteasome activity assay. In all lysates, success of the assay was defined as an increase in raw fluorescent units (RFU) detected from the first scan (0 min) to the fifth/final scan (120 min). For all of these analyses, 10 µM AMC was used as the highest standard for normalization of the raw fluorescent units (RFU). In the crude synaptic fraction, RFU peaked at scan 5 (Figure 3A), resulting in a normalized RFU of just under 0.1 (Figure 3B). In the cytoplasmic fraction, RFU increased across scans (Figure 3C) with a final normalized RFU of ~1.6 (Figure 3D). The nuclear fraction also displayed time-dependent changes in RFU (Figure 3E), with a final normalized RFU of 0.3 (Figure 3F). The differences in proteasome activity across compartments likely reflects the availability of proteasomes in the fraction, which are generally most abundant in the cytoplasm and nucleus27, compartments which have the highest level of activity in our preparation. The lowest level of activity in the synaptic region is consistent with it being the only lysate that was collected using ionic detergents, which can reduce proteasome activity due to the harsher denaturing condition. Importantly, RFU did not increase across time in the Assay Blanks or in lysates (synaptic) incubated with the highly specific and potent proteasome inhibitor clasto-lactacystin-β-lactone (Figure 3G, β-lac), displaying final normalized RFU levels of 0.01 and 0.001, respectively (Figure 3H). This suggests that the observed change in RFU was due specifically to activity of the proteasome and not other proteases. Furthermore, when analyzed across experimental conditions, there was an increase in nuclear, but not cytoplasmic, proteasome activity in the lateral amygdala following learning, which occurred simultaneously with a decrease in synaptic proteasome activity in comparison to control animals (Figure 4). Collectively, these results confirm that proteasome activity could be accurately measured in all three subcellular fractions collected from a single rat lateral amygdala.
One of the advantages of the proteasome activity assay is that in vitro manipulations can be introduced to the samples immediately prior to addition of the proteasome substrate, which allows identification of specific molecules which can regulate the proteasome in that particular subcellular fraction. As an example of this, the role of CaMKII (calcium/calmodulin dependent protein kinase II) was assessed in the synaptic fraction, the harshest denatured lysate collected, since CaMKII is thought to regulate proteasome function at synapses. A 30 min incubation with the CaMKII inhibitor myr-AIP (myristolayted autocamtide-2 related inhibitory peptide) resulted in a significantly diminished increase in proteasome activity on the assay, which only reached levels that were ~61% of the untreated controls (Figure 5A). Conversely, the same manipulation applied to the cytoplasmic did not result in a change in proteasome activity from vehicle treated wells (Figure 5B). These results confirm that proteasome activity can be further manipulated in vitro and that this manipulation can have different effects depending on the subcellular fraction collected.
In addition to quantifying proteasome activity, the described protocol can be used to measure subcellular differences in diverse ubiquitin modifications using Western blot procedures. It is important to note that the ubiquitin tags that can be detected are limited by the availability of linkage-specific antibodies, which currently include K48, K63 and M1 for rats (note: a K27 antibody is available, though did not produce a detectable image in any lateral amygdala fraction or whole cell lysates under a variety of conditions). Overall polyubiquitination, degradation-independent linear/M1 and K63 ubiquitination and degradation-specific K48 ubiquitination were detected in all subcellular fractions. Importantly, when analyzed across different experimental conditions, there was an increase in overall (Figure 6A), linear (Figure 6B), K63 (Figure 6C) and K48 (Figure 6D) polyubiquitination in the lateral amygdala nuclear fraction following learning in comparison to control animals. At the same time, in the cytoplasmic region, overall polyubiquitination decreased and K48 ubiquitination increased following learning, while synaptic K63 ubiquitination was reduced. Collectively, these results indicate that within the same animal subcellular differences in linkage-specific protein ubiquitination can be accurately detected.
Figure 1: Schematic for subcellular fractionation of rat brain tissue. Rodent brain is extracted, brain region dissected and hemispheres split. Using a series of buffers and centrifuging steps, nuclear and cytoplasmic fractions are collected from one hemisphere while a crude synaptic fraction is collected from the other. Both fractions are then used for proteasome activity assays and Western blotting, to assay protein polyubiquitination levels. Please click here to view a larger version of this figure.
Figure 2: Confirmation of crude synaptic, nuclear and cytoplasmic fraction purity. (A) The synaptic protein postsynaptic density protein 95 (PSD95; 1:1,000) was present in the synaptic, but not nuclear fraction with lower levels in the cytoplasm. (B) Histone H3 (1:500) was present in the nuclear, but not synaptic, fraction with lower expression in the cytoplasm. (C) β-Tubulin (1:1,000) was present in the cytoplasmic, but largely absent from the nuclear, fraction with lower expression in the synaptic lysate. (D) Housekeeping protein β-actin (1:1,000) was present in all subcellular compartments. Areas indicate the expected size of the target protein. This figure has been modified from Orsi, S.A. et al.21. Please click here to view a larger version of this figure.
Figure 3: Quantification of proteasome activity in nuclear, cytoplasmic and synaptic fractions collected from the lateral amygdala of the same animal. During the in vitro proteasome activity assay, relative fluorescent units (RFU) detected increased from the beginning (Scan 1) to the end (Scan 5) of the assay in the synaptic (A), Cytoplasmic (C) and nuclear (E) fractions. Quantification of this change from baseline indicated a normalized RFU value (relative to 10 μM AMC) of 0.1 in the synaptic (B), 1.6 in the cytoplasmic (D) and 0.3 in the nuclear (F) fractions. The proteasome inhibitor βlac prevented RFUs from changing across the session (G-H). This figure has been modified from Orsi, S.A. et al.21. Please click here to view a larger version of this figure.
Figure 4: Subcellular differences in proteasome activity in the lateral amygdala of the same animal. An increase in nuclear proteasome activity was detected in trained (fear conditioned) animals relative to controls, which corresponded to a decrease in activity within the synaptic fraction. Cytoplasmic proteasome activity remained at baseline. *P < 0.05 from Control. This figure has been modified from Orsi, S.A. et al.21. Please click here to view a larger version of this figure.
Figure 5: In vitro manipulation of proteasome activity in collected synaptic and cytoplasmic fractions. In vitro manipulation of CaMKII signaling via the inhibitor AIP reduced proteasome activity in the synaptic (A), but not the cytoplasmic (B), fraction from the rat lateral amygdala. This figure has been modified from Jarome, T.J. et al.23. Please click here to view a larger version of this figure.
Figure 6: Subcellular differences in linkage-specific protein ubiquitination in the lateral amygdala of the same animal following learning. (A) There was an increase in overall ubiquitination in the nuclear fraction following learning, which correlated with a decrease in the cytoplasmic fraction. (B) There was an increase in linear ubiquitination in the nuclear, but not cytoplasmic or synaptic, fraction following learning. (C) There was an increase in K63 ubiquitination in the nuclear fraction following learning, which correlated with a decrease in the synaptic fraction. (D) K48 ubiquitination increased in the nuclear and cytoplasmic, but not synaptic, fraction following learning. *P < 0.05 from Control. All obtained ubiquitin optical densities were normalized to β-actin levels (lower representative Western blot images in A), which was used as a loading control. This figure has been modified from Orsi, S.A. et al.21. Please click here to view a larger version of this figure.
Here, we demonstrate an efficient method for quantifying changes in ubiquitin-proteasome activity across different subcellular compartments in the same animal. Currently, most attempts at measuring subcellular changes in activity of the ubiquitin-proteasome system have been limited to a single compartment per sample, resulting in the need to repeat experiments. This leads to significant costs and loss of animal life. Our protocol alleviates this problem by splitting hemispheres, allowing different cellular fractions to be collected from each hemisphere of the same animal. Using this protocol, we were able to show for the first time that in the same animal ubiquitin-proteasome activity differentially changes in nuclear, cytoplasmic and synaptic fractions in response to learning21.
The main limitation of the protocol described here is it is reliant upon the amount of brain tissue (sample) obtained. For example, as outlined above, this protocol requires splitting hemispheres of a given brain region. However, this may not always be possible, such as in the case of certain areas that are only present in one hemisphere. In these cases, the protocol could be modified by first homogenizing the entire brain region in the TEVP buffer used in the synaptic fraction step (Section 3.1), since this buffer is free of all denaturing agents. The sample can then be split into two equal parts by volume. The first part can be used for the synaptic fraction, following the protocol as described. For the second half of the sample, the non-ionic detergent NP-40 can be added to a final concentration of 0.05%, followed by centrifuging as described in Section 2.6. This will allow the separation of cytoplasmic proteins into the supernatant and nuclear proteins into the pellet, which can be further isolated following the remaining steps in Section 2. Another concern in tissue quantity is that some brain regions are very small in size, such as the prelimbic cortex. However, in these cases, the above protocol can still be used by reducing the volumes of the buffers used, which would have to be determined empirically based on the size of the brain region collected. Thus, this protocol can be amended to even the more difficult brain regions in which less tissue is available.
One of the major advantages of the protocol we outline here is that it uses common laboratory equipment and reagents that can be found in most facilities, allowing this methodology to be amendable to those even on a restricted budget or with limited resources. Furthermore, while we outline this protocol as a way of measuring subcellular changes in ubiquitin-proteasome signaling, this methodology can also be applied to any other protein or cellular process in which understanding the cellular localization and function is important. Thus, this protocol could have broad applications to understanding the subcellular functions of specific proteins or complexes during learning and memory or different disease states.
The authors have nothing to disclose.
This work was supported by startup funds from the College of Agricultural and Life Sciences and the College of Science at Virginia Tech. T.M. is supported by the George Washington Carver Program at Virginia Tech.
0.5M EDTA | Fisher | 15575020 | Various other vendors |
20S Proteasome Activity Kit | Millipore Sigma | APT280 | Other vendors carry different versions |
ATP | Fisher | FERR1441 | Various other vendors |
Beta-actin antibody | Cell signaling | 4967S | Various other vendors |
Beta-tubulin antibody | Cell signaling | 2128T | Various other vendors |
BioTek Synergy H1 plate reader | BioTek | VATECHH1MT3 | Other vendors carry different versions |
B-mercaptoethanol | Fisher | ICN19024280 | Various other vendors |
clasto lactacystin b-lactone | Millipore Sigma | L7035 | Various other vendors |
Cryogenic cup | Fisher | 033377B | Various other vendors |
DMSO | DMSO | D8418 | Varous other vendors |
DTT | Millipore Sigma | D0632 | Various other vendors |
Glycerol | Millipore Sigma | G5516 | Various other vendors |
H3 antibody | Abcam | ab1791 | Various other vendors |
HEPES | Millipore Sigma | H3375 | Various other vendors |
Hydrochloric acid | Fisher | SA48 | Various other vendors |
IGEPAL (NP-40) | Millipore Sigma | I3021 | Various other vendors |
K48 Ubiquitin Antibody | Abcam | ab140601 | Various other vendors |
K63 Ubiquitin Antibody | Abcam | ab179434 | Various other vendors |
KCl | Millipore Sigma | P9541 | Various other vendors |
KONTES tissue grinder | VWR | KT885300-0002 | Various other vendors |
Laemmli sample buffer | Bio-rad | 161-0737 | Various other vendors |
Linear Ubiquitin Antibody | Life Sensors | AB-0130-0100 | Only M1 antibody |
MgCl | Millipore Sigma | 442611 | Various other vendors |
Microcentrifuge | Eppendorf | 2231000213 | Various other manufacturers/models |
myr-AIP | Enzo Life Sciences | BML-P212-0500 | Carried by Millipore-Sigma |
NaCl | Millipore Sigma | S3014 | Various other vendors |
Odyssey Fc Imaging System | LiCor | 2800-02 | Other vendors carry different versions |
Phosphatase Inhibitor | Millipore Sigma | 524625 | Various other vendors |
Precision Plus Protein Standard | Bio-rad | 161-0373 | Various other vendors |
Protease Inhibitor | Millipore Sigma | P8340 | Various other vendors |
PSD95 antibody | Cell signaling | 3450T | Various other vendors |
SDS | Millipore Sigma | L3771 | Various other vendors |
Sodium hydroxide | Fisher | SS255 | Various other vendors |
Sucrose | Millipore Sigma | S0389 | Various other vendors |
TBS | Alfa Aesar | J62938 | Varous other vendors |
Tris | Millipore Sigma | T1503 | Various other vendors |
Tween-20 | Fisher | BP337-100 | Various other vendors |
Ubiquitin Antibody | Enzo Life Sciences | BML-PW8810 | Various other vendors |